Open Access
Review
Epigenetic programming contributes to development of drug resistance in hematological malignancies
Qing-yuan Wang1,Hua Zhong1,*
1
Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
DOI: 10.2741/4333 Volume 20 Issue 4, pp.728-742
Published: 01 January 2015
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
*Corresponding Author(s):  
Hua Zhong
E-mail:  
zhh_lj@yeah.net
Abstract

Epigenetics is the study of long term and stable but not necessarily heritable alterations in transcriptional potential and gene expression profile of a cell that are not due to any alterations in the DNA sequence. Epigenetic modifications include DNA methylation, posttranslational modifications of histone proteins and expression of small regulatory RNAs. In recent years, the role of epigenetic modifications in the development of hematological malignancies and drug resistance has been studied in depth and has shed light on this important issue. Here, we review the major epigenetic mechanisms that contribute to the generation and evolution of hematological malignancies and development of resistance to chemotherapy. We will also discuss the development of epigenetic drugs that can overcome resistance to conventional chemotherapy.

Key words
Epigenetic Programming,Drug Resistance,Hematological Malignancies,Review
Share and Cite
Qing-yuan Wang, Hua Zhong. Epigenetic programming contributes to development of drug resistance in hematological malignancies. Frontiers in Bioscience-Landmark. 2015. 20(4); 728-742.